Francisco J. Esteva, MD, PhD

  • Specialty: Medical Oncology
  • Languages: English, Spanish
  • Phone: 212-731-5657

About Me

As a medical student, I was fascinated by internal medicine, a specialty that requires knowledge of multiple disciplines to reach accurate diagnoses and implement effective treatments. When I was a resident in internal medicine, I was inspired by cancer patients and the physicians and nurses who were in the trenches fighting this disease. I also became interested in the emerging field of molecular biology and its potential to revolutionize cancer therapy. I decided to become a medical oncologist to translate basic science concepts into bedside practices and improve patient outcomes.

I currently serve as the director of the breast medical oncology program at Perlmutter Cancer Center. Our program brings together surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, nurses, and other specialists to improve the lives of people with breast cancer through screening, prevention, and treatment.

My main focus is on using systemic therapies, such as endocrine therapy, targeted therapy, immunotherapy, and chemotherapy, to manage breast cancer at any stage.

My patients are unique individuals, not breast cancer subjects, and I treat them this way. I learn their history and combine this information with the results of a physical examination and imaging, as well as pathology and laboratory data, to make a diagnosis and determine the best course of treatment. I empower people to make treatment decisions with me, and I support them throughout their journey.

I currently lead clinical trials evaluating the safety and effectiveness of novel treatments for women with advanced breast cancer. Our research group, consisting of experts from a diverse array of specialties, is investigating how to improve the molecular classification of breast cancer. Our goal is to identify specific subtypes of breast cancer and design the appropriate treatment for each patient.

I have received the Mentored Patient-Oriented Research Career Development Award from the National Cancer Institute and been included in the “Best Doctors in America” list. I am also a fellow of the American College of Physicians and have been inducted into the American Society for Clinical Investigation, one of the oldest medical societies in the country.


Conditions and Treatments

breast cancer

Credentials

Positions
  • Professor, Department of Medicine
  • Assoc Dir of Clin Investigate Perlmutter CancerCtr
  • Dir Breast Medical Oncology Program
  • Co Dir Phase 1 Drug Dev Pgm Div Hematology Med Onc
  • Co Dir of the Breast Cancer DMG
Board Certifications
  • American Board of Internal Medicine (Medical Oncology), 1997
Education and Training
  • PhD from Zaragoza Medical School, 2001
  • Fellowship, Georgetown University Hospital, Medical Oncology, 1996
  • Residency, Cooper Hospital-Univ. Med. Center, Internal Medicine, 1994
  • MD from Zaragoza Medical School, 1988
Departments

Locations and Appointments

72 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Agewell
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield HealthPlus
  • Empire Blue Cross Blue Shield HealthPlus Essential
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Essential
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • GHI CBP
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP EPO/PPO
  • HIP HMO
  • HIP Medicare
  • HIP POS
  • HealthSmart (WTC)
  • Healthfirst
  • Healthfirst Essential
  • Hotel Trades
  • Humana Medicare
  • Independent Care System New York
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Essential
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MetroPlus Medicare
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • PHP
  • Tricare
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare Core and Charter
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Village Caremax
  • Visiting Nurse Service (VNS) Medicare
  • WellCare Child Health
  • WellCare Family Health
  • WellCare Medicaid
  • WellCare Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
NYU Medical Oncology Associates

160 East 34th Street
New York, NY 10016

Contact

Phone: 212-731-5657

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Publications

  • Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3 [Meeting Abstract]

    Fasching, P A; Jerusalem, G; Pivot, X; Martin, M; De, Laurentiis M; Blackwell, K; Esteva, F J; Paquet-Luzy, T; Tang, Z; Lorenc, K R; Slamon, D J
    Cancer research. 2016 15 Feb 2016. 76 (4):

  • DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer [Meeting Abstract]

    Gyorffy, B; Munkacsy, G; Esteva, F J; Miquel, T P; Menyhart, O
    Cancer research. 2016 15 Feb 2016. 76 (4):

  • A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC) [Meeting Abstract]

    Jhaveri, K; Teplinsky, E; Chandarlapaty, S; Solit, D; Cadoo, K; Speyer, J; D'Andrea, G; Adams, S; Patil, S; Haque, S; Friedman, K; Neville, D; Esteva, F; Hudis, C; Modi, S
    Cancer research. 2016 15 Feb 2016. 76 (4):

Read All Publications (141)